Want to see LFWD full AI Analyst Report?
LFWD Stock Chart & Stats
$7.11
-$0.16(-2.30%)
At close: 4:00 PM EDT
$7.11
-$0.16(-2.30%)
Day’s Range― - ―
52-Week Range$4.14 - $10.56
Previous CloseN/A
Volume3.69K
Average Volume (3M)316.99K
Market Cap
$20.73M
Enterprise Value$23.04
Total Cash (Recent Filing)$9.45M
Total Debt (Recent Filing)$2.56M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 17, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.82
Shares Outstanding2,832,016
10 Day Avg. Volume318,606
30 Day Avg. Volume316,993
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)9.55
Price to Sales (P/S)3.64
P/FCF Ratio-4.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside40.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.65
Revenue Forecast (FY)$28.78M
Bulls Say, Bears Say
Bulls Say
Reimbursement And Distribution ExpansionBroader reimbursement access and distribution can improve conversion of prospective users into paid exoskeleton purchases. These channels may support recurring demand and strengthen Lifeward’s market reach beyond individual clinical accounts.
Improved Liquidity And Operating DisciplineThe stronger cash position and lower operating cash use provide more flexibility to fund commercialization, product development and operational changes. This reduces immediate funding pressure, although continued losses mean external capital may still be needed.
Broader Mobility Product PlatformAdding upper-body technology broadens Lifeward’s addressable rehabilitation market beyond lower-limb disabilities and complements the ReWalk platform. If development reaches commercialization, the product could diversify revenue and improve long-term platform leverage.
Bears Say
Persistent Losses And Cash BurnVery large losses relative to revenue show that the cost structure has not scaled with business growth. Continued negative operating and free cash flow leaves Lifeward dependent on financing, limiting financial flexibility and increasing execution pressure.
Structural Margin PressureThe margin decline reduces the contribution available to fund research, sales and support activities. Tariffs and currency exposure may remain recurring risks, while lower production volumes indicate that manufacturing scale and absorption are not yet dependable.
Manufacturing And AlterG Execution RiskOperational changes have already disrupted shipment timing and contributed to a 22% quarterly revenue decline. Until the transition is stabilized, backlog conversion, production efficiency and revenue visibility remain vulnerable to further execution problems.
Lifeward News
LFWD FAQ
What was Lifeward’s price range in the past 12 months?
Lifeward lowest stock price was $4.14 and its highest was $10.56 in the past 12 months.
What is Lifeward’s market cap?
Lifeward’s market cap is $20.73M.
When is Lifeward’s upcoming earnings report date?
Lifeward’s upcoming earnings report date is Nov 17, 2026 which is in 86 days.
How were Lifeward’s earnings last quarter?
Lifeward released its earnings results on Aug 14, 2026. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$1.386 by -$0.074.
Is Lifeward overvalued?
According to Wall Street analysts Lifeward’s price is currently Undervalued.
Does Lifeward pay dividends?
Lifeward does not currently pay dividends.
What is Lifeward’s EPS estimate?
Lifeward’s EPS estimate is -0.79.
How many shares outstanding does Lifeward have?
Lifeward has 2,832,016 shares outstanding.
What happened to Lifeward’s price movement after its last earnings report?
Lifeward reported an EPS of -$1.46 in its last earnings report, missing expectations of -$1.386. Following the earnings report the stock price went down -5.636%.
Which hedge fund is a major shareholder of Lifeward?
Currently, no hedge funds are holding shares in LFWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lifeward
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
LFWD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.View all LFWD earnings summariesLFWD Stock 12 Month Forecast
Average Price Target
$10.00
▲(40.65% Upside)
Technical Analysis
Ownership Overview
14.89% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
85.07% Public Companies and
Individual Investors